Manila Times Business
Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided
Oslo, 26 June 2026 - Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. This concludes the previously communicated wrap-up phase of th
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Euronext announces completion of share repurchase programme as part of its long-term incentive plan
1h ago
EDF: EDF announces the signature of an agreement to sell EDF power solutions in the United States and Canada
1h ago
FDA Proposes Rule That Would Help Hold Foreign Tobacco Product Manufacturers Accountable, Protect Public Health
1h ago
A Moroccan court sentences 29 prominent people in major drug trafficking and corruption case
1h ago